Table 1.
Patient characteristics.
| Age (yr) (median [range]) | 59 (18–87) |
|---|---|
| Males (N(%)) | 145 (50.9) |
| Diabetes (N(%)) | 32 (11.2) |
| Hypertension (N(%)) | 105 (36.8) |
| Smoker (N(%)) | 51 (17.9) |
| Bulky disease (N(%)) | 112 (39.3) |
| Risk by IPI (N(%)) 0–1 2 3 4–5 |
79 (27.7) 59 (20.7) 61 (21.4) 86 (30.2) |
| Chemotherapeutic regimen (N(%)) R-CHOEP 14 DA-R-EPOCH R-CHOP R-CEOP/ R-miniCHOP |
81 (28.4) 36 (12.6) 137 (48.1) 31 (10.9) |
| Involved site radiotherapy Yes (N(%)) | 148 (51.9) |
| Response (N(%)) Complete remission Partial remission Stable disease Progressive disease Toxic death |
229 (80.4) 26 (9.1) 14 (4.9) 4 (1.4) 12 (4.2) |
| Creatinine (μmol/L) (mean ± SD) | 81.9 ± 1.3 |
| GFR (mL/min/1.73 m2) (mean ± SD) | 84.5 ± 1.5 |
| GFR < 60 mL/min/1.73 m2 (N(%)) | 44 (15.4) |
| GFR < 90 mL/min/1.73 m2 (N(%)) | 167 (58.6) |
DA-R-EPOCH = dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab, GFR = glomerular filtration rate, IPI = international prognostic index, R-CEOP = cyclophosphamide, vincristine, prednisone, etoposide and rituximab, R-CHOEP = cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide and rituximab, R-CHOP = cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab.